

> Return address PO Box 320, 1110 AH Diemen

Minister of Medical Care and Sports
PO Box 20350
2500 EJ THE HAGUE

2020053584

Date 16 December 2020
Subject GVS advice concerning romosozumab (Evenity®)

**National Health Care
Institute**

Care I
Willem Dudokhof 1
1112 ZA Diemen
PO Box 320
1110 AH Diemen
www.zorginstituutnederland.nl
info@zinl.nl

T +31 (0)20 797 85 55

Contact

Ms. J.M. van der Waal
T +31 (0)6 120 017 28

Our reference
2020053584

Dear Ms van Ark,

In your letter of 10 November 2020 (CIBG-20-1121), you asked the National Health Care Institute to assess whether romosozumab (Evenity®) is interchangeable with a product that is included in the Medicine Reimbursement System (GVS). The National Health Care Institute has since completed its assessment. The considerations are included in the GVS report attached to this letter.

Romosozumab (Evenity®) is indicated for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

Romosozumab is available as a pre-filled syringe; each pre-filled syringe contains 105 mg romosozumab in 1.17 ml solution (90 mg/ml). The recommended dose is 210 mg romosozumab (administered as two subcutaneous injections of 105 mg each) once monthly for 12 months.

Assessment outcome

The National Health Care Institute has concluded that romosozumab has added therapeutic value in comparison with alendronate (oral), and that the therapeutic value is comparable with that of teriparatide (subcutaneous) in patients with postmenopausal osteoporosis and a very high risk of fracture.

Review of interchangeability

Based on the criteria for interchangeability, it can be concluded that romosozumab (Evenity®) is interchangeable with teriparatide, which is included in GVS cluster OH05AAAP V.

Advice

Based on the above, we recommend that you include romosozumab (Evenity®) in cluster 0H05AAAP V on List 1A of the GVS. 6.9 mg/day can be applied as the standard dose.

Yours sincerely,

Sjaak Wijma
Chair of the Executive Board

**National Health Care
Institute**
Care I

Date
16 December 2020

Our reference
2020053584